{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:12:08Z","timestamp":1790313128751,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Heat shock protein 70 (Hsp70) which is frequently overexpressed in many different cancer types is also present on the plasma membrane of tumor but not normal cells. The intensity of membrane-expressed Hsp70 (mHsp70) is associated with disease progression and treatment resistance. It has also been shown that Hsp70 can be actively released into the circulation by mHsp70 positive, viable tumor cells in the form of extracellular lipid microvesicles expressing mHsp70, the levels of which might therefore act as a potential biomarker for tumor aggressiveness in lung malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Extracellular Hsp70 (eHsp70) was measured in the plasma of patients with non-small cell lung cancer (<jats:italic>n<\/jats:italic>\u2009=\u2009178, NSCLC) and lung metastases of extrathoracic tumors (<jats:italic>n<\/jats:italic>\u2009=\u200935) prior to surgery using the Hsp70-exo ELISA which detects microvesicle-associated eHsp70 and the patient`s immunophenotype was determined by flow cytometric analysis of the corresponding peripheral blood lymphocytes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>eHsp70 values were significantly higher in patients with NSCLC than in healthy individuals, with no differences between adeno and squamous cell carcinomas. Levels of circulating eHsp70 which are associated with the Programmed cell death protein 1 (PD-L1) status, gradually increased from early stage to metastatic disease, and patients with lymph node metastases in surgically treatable NSCLC had significantly higher eHsp70 levels than nodal negative patients. In all tumor stages, total lymphocyte counts were significantly reduced and immunoregulatory T (Treg) cell counts were increased compared to healthy controls. Lower CD4\u2009+\u2009T helper cell and higher CD3-\/CD56+\/CD94+\/CD69+\/NKp30+\/NKp46\u2009+\u2009NK cell ratios were only found in patients with thoracic metastases of other primary tumors. An early relapse after complete resection with curative intent correlated with significantly elevated eHsp70 levels which were measured prior to surgery, in all thoracic cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In summary, we propose circulating eHsp70 levels before any treatment as a predictive biomarker for the presence of lymph node metastases and early therapy failure in patients with thoracic malignancies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14725-5","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:52:43Z","timestamp":1754740363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse in thoracic cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Dominik","family":"Lobinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Messner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Seier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bodner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Bashiri","family":"Dezfouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Graham","family":"Pockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyer","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Multhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"14725_CR1","unstructured":"(WHO) WHO. Lung cancer. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer"},{"key":"14725_CR2","unstructured":"Robert Koch Institute (ed) and the Association of Population-based Cancer Registries in Germany (ed) Berlin. Cancer in Germany 2019\/2020 14th edition."},{"issue":"2","key":"14725_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.lungcan.2014.12.006","volume":"87","author":"F Kocher","year":"2015","unstructured":"Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer. 2015;87(2):193\u2013200.","journal-title":"Lung Cancer"},{"issue":"1","key":"14725_CR4","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14725_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12885-020-06738-z","volume":"20","author":"F Hardtstock","year":"2020","unstructured":"Hardtstock F, Myers D, Li T, Cizova D, Maywald U, Wilke T, et al. Real-world treatment and survival of patients with advanced non-small cell lung cancer: a German retrospective data analysis. BMC Cancer. 2020;20(1):260.","journal-title":"BMC Cancer"},{"issue":"7689","key":"14725_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"issue":"5","key":"14725_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"14725_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","volume":"23","author":"M Araghi","year":"2023","unstructured":"Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1):162.","journal-title":"Cancer Cell Int"},{"key":"14725_CR9","doi-asserted-by":"crossref","unstructured":"de Jong D, Das JP, Ma H, Pailey Valiplackal J, Prendergast C, Roa T, et al. Novel targets, novel treatments: the changing landscape of non-small cell lung cancer. Cancers (Basel). 2023;15(10).","DOI":"10.3390\/cancers15102855"},{"issue":"1","key":"14725_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/a-2175-4580","volume":"78","author":"TG Blum","year":"2024","unstructured":"Blum TG, Vogel-Claussen J, Andreas S, Bauer TT, Barkhausen J, Harth V, et al. Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings. Pneumologie. 2024;78(1):15\u201334.","journal-title":"Pneumologie"},{"issue":"19","key":"14725_CR11","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1073\/pnas.82.19.6455","volume":"82","author":"C Hunt","year":"1985","unstructured":"Hunt C, Morimoto RI. Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70. Proc Natl Acad Sci U S A. 1985;82(19):6455\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"14725_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1189\/jlb.0306167","volume":"81","author":"E Schmitt","year":"2007","unstructured":"Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 2007;81(1):15\u201327.","journal-title":"J Leukoc Biol"},{"issue":"5561","key":"14725_CR13","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1126\/science.1068408","volume":"295","author":"FU Hartl","year":"2002","unstructured":"Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002;295(5561):1852\u20138.","journal-title":"Science"},{"issue":"2","key":"14725_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ijc.2910610222","volume":"61","author":"G Multhoff","year":"1995","unstructured":"Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer. 1995;61(2):272\u20139.","journal-title":"Int J Cancer"},{"issue":"12","key":"14725_CR15","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1158\/0008-5472.CAN-04-3804","volume":"65","author":"R Gastpar","year":"2005","unstructured":"Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005;65(12):5238\u201347.","journal-title":"Cancer Res"},{"key":"14725_CR16","doi-asserted-by":"publisher","first-page":"1388999","DOI":"10.3389\/fonc.2024.1388999","volume":"14","author":"B Hu","year":"2024","unstructured":"Hu B, Liu G, Zhao K, Zhang G. Diversity of extracellular HSP70 in cancer: advancing from a molecular biomarker to a novel therapeutic target. Front Oncol. 2024;14:1388999.","journal-title":"Front Oncol"},{"issue":"2A","key":"14725_CR17","first-page":"1015","volume":"21","author":"E Malusecka","year":"2001","unstructured":"Malusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res. 2001;21(2A):1015\u201321.","journal-title":"Anticancer Res"},{"issue":"6","key":"14725_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1046\/j.1440-1746.2003.03011.x","volume":"18","author":"TS Hwang","year":"2003","unstructured":"Hwang TS, Han HS, Choi HK, Lee YJ, Kim YJ, Han MY, et al. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol. 2003;18(6):690\u2013700.","journal-title":"J Gastroenterol Hepatol"},{"key":"14725_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers13153706","volume":"13","author":"C Werner","year":"2021","unstructured":"Werner C, Stangl S, Salvermoser L, Schwab M, Shevtsov M, Xanthopoulos A, et al. Hsp70 in liquid Biopsies-A Tumor-Specific biomarker for detection and response monitoring in cancer. Cancers (Basel). 2021;13:15.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"14725_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ijrobp.2013.11.008","volume":"88","author":"C Bayer","year":"2014","unstructured":"Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, et al. Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models. Int J Radiat Oncol Biol Phys. 2014;88(3):694\u2013700.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"14725_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.plipres.2019.01.004","volume":"74","author":"Z Balogi","year":"2019","unstructured":"Balogi Z, Multhoff G, Jensen TK, Lloyd-Evans E, Yamashima T, Jaattela M, et al. Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. Prog Lipid Res. 2019;74:18\u201330.","journal-title":"Prog Lipid Res"},{"issue":"2","key":"14725_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1073\/pnas.1016065108","volume":"108","author":"S Stangl","year":"2011","unstructured":"Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A. 2011;108(2):733\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14725_CR23","doi-asserted-by":"publisher","first-page":"669366","DOI":"10.3389\/fmolb.2021.669366","volume":"8","author":"D Lobinger","year":"2021","unstructured":"Lobinger D, Gempt J, Sievert W, Barz M, Schmitt S, Nguyen HT, et al. Potential role of Hsp70 and activated NK cells for prediction of prognosis in glioblastoma patients. Front Mol Biosci. 2021;8:669366.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"14725_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jtho.2022.12.004","volume":"18","author":"ME Marmarelis","year":"2023","unstructured":"Marmarelis ME, Sun L, Aggarwal C. Adjuvant Atezolizumab should be administered to all patients with programmed Death-Ligand 1 expressing surgically resected stage II to III NSCLC after chemotherapy: in favor. J Thorac Oncol. 2023;18(3):265\u20137.","journal-title":"J Thorac Oncol"},{"issue":"10308","key":"14725_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357.","journal-title":"Lancet"},{"issue":"2","key":"14725_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cas.16030","volume":"115","author":"T Mitsudomi","year":"2024","unstructured":"Mitsudomi T, Ito H, Okada M, Sugawara S, Shio Y, Tomii K, et al. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from checkmate 816. Cancer Sci. 2024;115(2):540\u201354.","journal-title":"Cancer Sci"},{"issue":"17","key":"14725_CR27","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.22.02509","volume":"41","author":"O Akinboro","year":"2023","unstructured":"Akinboro O, Drezner N, Amatya A, Runyan J, Fourie-Zirkelbach J, Zhao M, et al. US food and drug administration approval summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer. J Clin Oncol. 2023;41(17):3249\u201359.","journal-title":"J Clin Oncol"},{"issue":"21","key":"14725_CR28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"3","key":"14725_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtcvs.2023.04.039","volume":"166","author":"P Expert Consensus","year":"2023","unstructured":"Expert Consensus P, Kidane B, Bott M, Spicer J, Backhus L, Chaft J, et al. The American association for thoracic surgery (AATS) 2023 expert consensus document: staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023;166(3):637\u201354.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"14725_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","volume":"20","author":"D Marinelli","year":"2025","unstructured":"Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, et al. Improved Event-Free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis. J Thorac Oncol. 2025;20(3):285\u201395.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"14725_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-022-01505-z","volume":"21","author":"W Li","year":"2022","unstructured":"Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1):25.","journal-title":"Mol Cancer"},{"issue":"2","key":"14725_CR32","first-page":"539","volume":"1846","author":"C Rolfo","year":"2014","unstructured":"Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014;1846(2):539\u201346.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"14725_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000152945","volume":"29","author":"F Blankenburg","year":"2008","unstructured":"Blankenburg F, Hatz R, Nagel D, Ankerst D, Reinmiedl J, Gruber C, et al. Preoperative CYFRA 21\u2013\u20091 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol. 2008;29(4):272\u20137.","journal-title":"Tumour Biol"},{"issue":"2","key":"14725_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","volume":"76","author":"M Grunnet","year":"2012","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138\u201343.","journal-title":"Lung Cancer"},{"issue":"6","key":"14725_CR35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jso.23293","volume":"107","author":"T Kato","year":"2013","unstructured":"Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status. J Surg Oncol. 2013;107(6):619\u201324.","journal-title":"J Surg Oncol"},{"issue":"3","key":"14725_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejcts.2007.05.014","volume":"32","author":"K Matsuoka","year":"2007","unstructured":"Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32(3):435\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3B","key":"14725_CR37","first-page":"2177","volume":"20","author":"K Hotta","year":"2000","unstructured":"Hotta K, Segawa Y, Takigawa N, Kishino D, Saeki H, Nakata M, et al. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer. Anticancer Res. 2000;20(3B):2177\u201380.","journal-title":"Anticancer Res"},{"issue":"2","key":"14725_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.athoracsur.2006.07.079","volume":"83","author":"WH Hsu","year":"2007","unstructured":"Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang BS, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83(2):419\u201324.","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"14725_CR39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1200\/JCO.19.02748","volume":"38","author":"BJ Schneider","year":"2020","unstructured":"Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, et al. Lung Cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. 2020;38(7):753\u201366.","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"14725_CR40","doi-asserted-by":"publisher","first-page":"eS437","DOI":"10.1378\/chest.12-2365","volume":"143","author":"HG Colt","year":"2013","unstructured":"Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):eS437\u201354.","journal-title":"Chest"},{"key":"14725_CR41","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Version 4.0-April 2025. 2025;AWMF-Registernummer: 020-007OL."},{"issue":"4","key":"14725_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.7314\/APJCP.2012.13.4.1137","volume":"13","author":"XL Ma","year":"2012","unstructured":"Ma XL, Xiao ZL, Liu L, Liu XX, Nie W, Li P, et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev. 2012;13(4):1137\u201344.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"14725_CR43","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/ijc.25819","volume":"129","author":"V Hofman","year":"2011","unstructured":"Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, et al. Detection of Circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the cellsearch assay and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129(7):1651\u201360.","journal-title":"Int J Cancer"},{"issue":"4","key":"14725_CR44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/1078-0432.CCR-10-0445","volume":"17","author":"V Hofman","year":"2011","unstructured":"Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, et al. Preoperative Circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17(4):827\u201335.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"14725_CR45","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jtho.2023.07.005","volume":"18","author":"T Sikosek","year":"2023","unstructured":"Sikosek T, Horos R, Trudzinski F, Jehn J, Frank M, Rajakumar T, et al. Early detection of lung Cancer using small RNAs. J Thorac Oncol. 2023;18(11):1504\u201323.","journal-title":"J Thorac Oncol"},{"key":"14725_CR46","doi-asserted-by":"crossref","unstructured":"Seier S, Bashiri Dezfouli A, Lennartz P, Pockley AG, Klein H, Multhoff G. Elevated levels of circulating Hsp70 and an increased prevalence of CD94+\/CD69\u2009+\u2009NK cells is predictive for advanced stage non-small cell lung cancer. Cancers (Basel). 2022;14(22).","DOI":"10.3390\/cancers14225701"},{"issue":"6","key":"14725_CR47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00018-004-4464-6","volume":"62","author":"MP Mayer","year":"2005","unstructured":"Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci. 2005;62(6):670\u201384.","journal-title":"Cell Mol Life Sci"},{"key":"14725_CR48","doi-asserted-by":"crossref","unstructured":"Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM. HSP70 multi-functionality in cancer. Cells. 2020;9(3).","DOI":"10.3390\/cells9030587"},{"issue":"6","key":"14725_CR49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/carcin\/bgt111","volume":"34","author":"ME Murphy","year":"2013","unstructured":"Murphy ME. The HSP70 family and cancer. Carcinogenesis. 2013;34(6):1181\u20138.","journal-title":"Carcinogenesis"},{"issue":"1","key":"14725_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00666207","volume":"32","author":"SA Fuqua","year":"1994","unstructured":"Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994;32(1):67\u201371.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"14725_CR51","doi-asserted-by":"publisher","first-page":"e1925","DOI":"10.1371\/journal.pone.0001925","volume":"3","author":"M Gehrmann","year":"2008","unstructured":"Gehrmann M, Liebisch G, Schmitz G, Anderson R, Steinem C, De Maio A, et al. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS ONE. 2008;3(4):e1925.","journal-title":"PLoS ONE"},{"key":"14725_CR52","doi-asserted-by":"crossref","unstructured":"Xanthopoulos A, Samt AK, Guder C, Taylor N, Roberts E, Herf H, et al. Hsp70-A universal biomarker for predicting therapeutic failure in human female cancers and a target for CTC isolation in advanced cancers. Biomedicines. 2023;11(8).","DOI":"10.3390\/biomedicines11082276"},{"issue":"11","key":"14725_CR53","first-page":"5466","volume":"11","author":"JA Baek","year":"2018","unstructured":"Baek JA, Choi JH, Gu MJ. The loss of CD44 and HSP70 overexpression is related to aggressive clinicopathologic factors in prostate cancer. Int J Clin Exp Pathol. 2018;11(11):5466\u201372.","journal-title":"Int J Clin Exp Pathol"},{"key":"14725_CR54","doi-asserted-by":"crossref","unstructured":"Safi S, Messner L, Kliebisch M, Eggert L, Ceylangil C, Lennartz P, et al. Circulating Hsp70 levels and the immunophenotype of peripheral blood lymphocytes as potential biomarkers for advanced lung cancer and therapy failure after surgery. Biomolecules. 2023;13(5).","DOI":"10.3390\/biom13050874"},{"key":"14725_CR55","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3389\/fimmu.2015.00556","volume":"6","author":"S Gunther","year":"2015","unstructured":"Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, et al. Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno Non-Small cell lung cancer. Front Immunol. 2015;6:556.","journal-title":"Front Immunol"},{"key":"14725_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1748-717X-9-131","volume":"9","author":"M Gehrmann","year":"2014","unstructured":"Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, et al. Hsp70\u2013a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Radiat Oncol. 2014;9:131.","journal-title":"Radiat Oncol"},{"issue":"3 Suppl","key":"14725_CR57","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1378\/chest.07-1360","volume":"132","author":"GA Silvestri","year":"2007","unstructured":"Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):S178\u2013201.","journal-title":"Chest"},{"issue":"11","key":"14725_CR58","doi-asserted-by":"publisher","first-page":"879","DOI":"10.7326\/0003-4819-139-11-200311180-00013","volume":"139","author":"MK Gould","year":"2003","unstructured":"Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139(11):879\u201392.","journal-title":"Ann Intern Med"},{"issue":"2","key":"14725_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3413\/nukmed-0217","volume":"48","author":"D Hellwig","year":"2009","unstructured":"Hellwig D, Baum RP, Kirsch C, FDG-PET, PET\/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48(2):59\u201369. quiz N8-9.","journal-title":"Nuklearmedizin"},{"issue":"5 Suppl","key":"14725_CR60","doi-asserted-by":"publisher","first-page":"eS211","DOI":"10.1378\/chest.12-2355","volume":"143","author":"GA Silvestri","year":"2013","unstructured":"Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):eS211\u201350.","journal-title":"Chest"},{"issue":"2","key":"14725_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cllc.2011.08.002","volume":"13","author":"J Wang","year":"2012","unstructured":"Wang J, Welch K, Wang L, Kong FM. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2012;13(2):81\u20139.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"14725_CR62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.21037\/tlcr.2020.03.08","volume":"10","author":"V Leiro-Fernandez","year":"2021","unstructured":"Leiro-Fernandez V, Fernandez-Villar A. Mediastinal staging for non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(1):496\u2013505.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"14725_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13014-019-1286-0","volume":"14","author":"A Rothammer","year":"2019","unstructured":"Rothammer A, Sage EK, Werner C, Combs SE, Multhoff G. Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy-potential markers for predicting breast cancer recurrence? Radiat Oncol. 2019;14(1):78.","journal-title":"Radiat Oncol"},{"issue":"11","key":"14725_CR64","first-page":"1627","volume":"27","author":"G Multhoff","year":"1999","unstructured":"Multhoff G, Mizzen L, Winchester CC, Milner CM, Wenk S, Eissner G, et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. ExpHematol. 1999;27(11):1627\u201336.","journal-title":"ExpHematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14725-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14725-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:53:09Z","timestamp":1757346789000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14725-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14725"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14725-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee of the TUM School of Medicine and Health (ethical approval number: 2403\/09 and 2428\/09), and written informed consent was obtained from all patients and healthy donors before start of the study. Blood sampling was conducted in accordance to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AGP is CEO and GM is CSO of multimmune GmbH. A granted US patent protects the Hsp70-exo ELISA for determining free and vesicular eHsp70 in liquid biopsies. All other authors [DL, NT, VM, SS (Seier), JB, ER, AD, SS (Safi)] have no known competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1297"}}